Company

Mitobridge (acquired by Astellas)

Last updated 2026-05-30· 1 min read

Reviewed by the Ultimate Longevity Bible editorial team. Educational reference — not medical advice. See disclaimer.

What it was

Mitobridge was founded in 2014 to develop drugs targeting mitochondrial dysfunction across muscle, metabolic, and neurological diseases. Acquired by Astellas Pharma in 2018 for $225M upfront + milestones.

Now operates as part of Astellas’ mitochondrial-disease franchise.

Programmes

PPARδ agonists for primary mitochondrial myopathy, ALS, Duchenne muscular dystrophy, and metabolic indications.
Other mitochondrial-targeted pre-clinical programmes inherited by Astellas.

Why it’s in this reference

Mitobridge represents the first wave of mitochondrial-medicine biotechs to reach mainstream pharma acquisition. The thesis — that targeting mitochondrial function is a tractable drug-development strategy — has been validated commercially.

Subsequent mitochondrial-focused biotechs (Stealth BioTherapeutics, Imel Biotherapeutics, others) build on the foundation Mitobridge helped establish.

Historical context

MitoBridge Pharmaceuticals was founded in 2014 by veteran biotech executives out of Third Rock Ventures with a mitochondrial-metabolism focus. Astellas acquired MitoBridge in 2018 for ~$450M, folding the programmes into Astellas's Institute for Regenerative Medicine efforts.

What they were pursuing

MitoBridge's lead assets targeted PPAR-delta activation and other mitochondrial-biogenesis mechanisms, aiming at rare mitochondrial diseases with a longer-term view toward age-related decline in mitochondrial function.

Status post-acquisition

Post-acquisition programmes have progressed under Astellas branding. The MitoBridge acquisition is often cited as an early example of a major pharma company buying into the mitochondrial-therapeutics thesis — a bellwether for how mainstream pharma views the mitochondrial dysfunction hallmark.